Medcura Appoints Surgical Medical Devices Leader Jim Buck as CEO
An experienced technology-driven innovator aims to position and accelerate the company’s first–kind surgical technology platform
Riverdale, MD., June 6, 2022 /PRNewswire/ — Medcura, Inc.a commercial company specializing in life sciences and medical devices, has appointed James (Jim) Buck as Chief Executive Officer (CEO). A globally connected leader, Buck has been a director at Medcura since 2018 and now fully assumes the role of CEO with over 25 years of highly relevant professional experience. From innovative and ambitious start-ups to the world’s largest healthcare companies, Buck has successfully developed and commercialized many innovative medical technologies.
“Jim is exactly the type of proven engine that Medcura needs right now to accelerate our first-of-its-kind surgical technology platform,” said larry tiffany, the current CEO of Medcura. “With remarkable skills, new strategies and a wealth of expertise, Jim takes the helm at an exciting time when our cutting-edge, easy-to-use and affordable hemostat is fast becoming a surgical standard. I have no Doubt on Jim will usher in a new phase of growth for our frontline business in a way that will benefit surgeons, patients, the military and consumers.” Tiffany is stepping down as CEO of Medcura after more than five years of building the company from concept to initial commercialization, and will continue to work full-time with the company as executive director and president.
Buck’s track record of leading world-class teams with next-generation technologies includes transforming businesses for long-term success and profitability. With experience optimizing products for several high-impact device companies, Buck is confident he can successfully lead Medcura through its next steps of rapid value creation with a focus on its core surgical product. and its platform which are likely to include other notable and valuable product embodiments. , applications and innovations.
“Medcura is a company on the move with a very bright future,” Buck said. “Our proprietary biosurgical gel technology has repeatedly demonstrated the ability to reliably stop difficult-to-control surgical bleeding with industry-leading and disruptive cost savings in many challenging preclinical models. The inherent versatility of our technology allows for platform extensions to highly differentiated product solutions, best exemplified in our new surgical and consumer product applications.I am excited to guide Medcura through this next phase of rapid growth as we move towards regulatory approvals for products high-value implantables and global commercialization.
Prior to assuming this role at Medcura, Buck served as President and CEO of cancer imaging innovator ClearCut Medical. Prior to ClearCut, Buck was President and CEO of globally recognized developer of heart valve therapies, Mardil Medical. Previously, he was also Vice President of Marketing and Business Development at one of the biosurgical industry’s most successful new technology companies, Closure Medical. There, Buck led the product mapping strategy and execution of a breakthrough surgical sealant and adhesive technology, acquired by global healthcare leader, Johnson & Johnson, for more than $370 million. He also held several management and executive positions at cardiac medical device leader St. Jude Medical, Inc. for more than a decade after earning a Masters of Commerce degree from Northwestern University.
At Medcura, Buck will guide a growing team provide the necessary solutions in the operating room and beyond. Together, Buck and Tiffany bring extensive business, financial, and regulatory experience in growing and scaling businesses, R&D, and development and manufacturing of FDA-approved medical devices. With such strengths, Medcura has had recent success in launching its range of consumer productsthe accelerated scale-up of its manufacturing processes and numerous ongoing clinical and preclinical demonstrations of safety and efficacy across its multiple verticals while validating surgical preclinical models.
Medcura is a commercial-stage life science and medical device company that develops general-purpose hemostatic products for surgical, military and consumer applications. The company combines the use of safe, inert ingredients with proprietary chemistry to address significant unmet market needs. Medcura’s mission is to pursue the development and commercialization of a wide range of breakthrough wound care and hemostatic products, including its revolutionary military device, LifeFoam™, which leads the expansion of Medcura’s technology platform. for internal use. For more information about Medcura, visit medcurainc.com.
Inspire agency on behalf of Medcura